TradeFlare's AI research teams analysed IRWD on 4 market nights between May 13, 2026 and July 16, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| July 16, 2026 | BUY | $4.00 | — / — | -2.1% | +5.4% | Continued positive momentum for LINZESS and progress on apraglutide development. |
| July 15, 2026 | BUY | $3.98 | — / — | -3.0% | +8.0% | The stock is currently at resistance and has a bearish fundamental outlook, making a buy recommendation inappropriate. |
| May 14, 2026 | BUY | $3.68 | — / — | +4.9% | -0.5% | Continued strong performance of LINZESS. |
| May 13, 2026 | HOLD | $4.09 | — / — | +6.5% | -1.4% | Continued strong performance and growth of LINZESS. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.